SecBot SecBot
SECBOTREPLAY Home › Report › DRTSW

DRTSW · Alpha Tau presented interim data from its REGAIN trial of Alpha DaRT…

Alpha Tau Medical Ltd. · 6-K filed May 11, 2026 at 09:29 ET

At the news

BULLISHIMPACT 7/10

6-K filed May 11, 2026 at 09:29 ET

Alpha Tau presented interim data from its REGAIN trial of Alpha DaRT for recurrent glioblastoma (GBM). Of the first three patients treated, two achieved complete responses and one stable disease with a 30% tumor reduction, with no unanticipated side effects. This is a strong early efficacy signal in a difficult-to-treat indication, though the sample is small and further enrollment and FDA review are pending.

  • 3 patients treated in REGAIN trial for recurrent GBM
  • 2 complete responses and 1 stable disease (30% size reduction) as of May 3, 2026
  • No unanticipated side effects; grade 2-3 seizures occurred in 2 patients but resolved to baseline
  • Plan to enroll 10 patients total pending FDA interim safety review

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access